▎Armstrong2025年12月6-9日,美国血液学会年会(ASH)在美国佛罗里达州奥兰多举办,乐普生物CD20 ADC新药MRG001+BTK抑制剂奥布替尼联合治疗DLBCL的二期临床最新数据将在此次大会上报告。截至2025年8月31日,该II期研究共入组26例R/R DLBCL患者,所有患者均接受过至少1线标准治疗失败,80.8%的患者接受过2线及以上治疗,既往治疗线数中位数为3线(1-...
Source Link▎Armstrong2025年12月6-9日,美国血液学会年会(ASH)在美国佛罗里达州奥兰多举办,乐普生物CD20 ADC新药MRG001+BTK抑制剂奥布替尼联合治疗DLBCL的二期临床最新数据将在此次大会上报告。截至2025年8月31日,该II期研究共入组26例R/R DLBCL患者,所有患者均接受过至少1线标准治疗失败,80.8%的患者接受过2线及以上治疗,既往治疗线数中位数为3线(1-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.